Journal issues > Issue Special, March 2024 > Updates in the management of renal cell Carcinoma

Updates in the management of renal cell Carcinoma

The opening session of the 2024 Belgian Multidisciplinary Meeting on Urological Cancers (BMUC) highlighted key advancements in renal cell carcinoma (RCC) management. Prof. Christine Gennigens (ULiège, Liège, Belgium) presented current and future strategies for first-line metastatic RCC treatment, emphasising options such as immunotherapy (IO) dual combinations, IO plus tyrosine kinase inhibitor (TKI) regimens, TKI monotherapy, and triplet therapies. Additionally, Prof. Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discussed the promising outcomes of stereotactic ablative body radiotherapy (SABR) in primary RCC, underscoring its advantages over traditional approaches like surgery or thermal ablation.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top